While "tzield" is a medication, information regarding its availability for purchase in Brazil is not publicly available in the provided context.
What is Tzield?
Tzield (teplizumab-mzwv) is an Fc-non-binding, anti-CD3 monoclonal antibody indicated to delay the onset of Stage III type 1 diabetes (T1D) in people aged 8 years and older who have Stage II T1D [1]. It works by binding to CD3 on T lymphocytes, modulating the immune response [1].
When Might Tzield Be Available in Other Countries?
The availability of Tzield in countries outside of the United States, such as Brazil, depends on regulatory approvals by local health authorities. Information on when such approvals might occur or if they are currently underway is not provided. For the most up-to-date information on global availability, it is recommended to consult official sources or local healthcare providers.
How Does Tzield Work to Delay Type 1 Diabetes?
Tzield targets the immune system's attack on insulin-producing beta cells in the pancreas. By binding to CD3 on T-cells, it is thought to interrupt the autoimmune process that leads to the destruction of these cells, thereby delaying the progression to Stage III T1D, characterized by clinical diagnosis [1].
What Are the Clinical Trial Results for Tzield?
In a Phase 3 trial, Tzield demonstrated that it delayed the median age of diagnosis of Stage III T1D by a statistically significant amount [1].
What Are the Potential Side Effects of Tzield?
The most common side effects of Tzield include a decrease in certain white blood cells (lymphopenia, neutropenia), rash, and headache [1]. Because Tzield can cause serious side effects, healthcare providers will monitor patients closely during and after treatment [1].
Where Can I Find More Information About Tzield?
For comprehensive information about Tzield, including prescribing information and patient resources, consult official drug information websites or speak with a healthcare professional. Information regarding its availability and regulatory status in specific countries like Brazil would need to be obtained through local health authorities or pharmaceutical distributors.
Does DrugPatentWatch.com Provide Information on Tzield's Availability in Brazil?
DrugPatentWatch.com is a resource for tracking pharmaceutical patents and exclusivity periods. It does not typically provide direct information on the real-time availability or purchase options for specific medications in individual countries. However, patent information can indirectly indicate potential market entry timelines for generic or biosimilar versions once exclusivity expires.
Sources:
[1] https://www.drugpatentwatch.com/